Twin Capital Management’s Bristol-Myers Squibb BMY Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$4.74M Buy
78,220
+218
+0.3% +$12.7K 0.61% 30
2025
Q4
$4.21M Sell
78,002
-1,122
-1% -$54K 0.52% 41
2025
Q3
$3.57M Sell
79,124
-30,315
-28% -$1.42M 0.45% 54
2025
Q2
$5.07M Buy
109,439
+908
+0.8% +$44.6K 0.54% 41
2025
Q1
$6.62M Buy
108,531
+16,437
+18% +$958K 0.77% 22
2024
Q4
$5.21M Buy
92,094
+9,245
+11% +$517K 0.57% 33
2024
Q3
$4.29M Buy
82,849
+22,080
+36% +$1.04M 0.48% 48
2024
Q2
$2.52M Sell
60,769
-18,087
-23% -$809K 0.3% 94
2024
Q1
$4.28M Sell
78,856
-4,306
-5% -$219K 0.53% 46
2023
Q4
$4.27M Buy
83,162
+9,831
+13% +$516K 0.56% 43
2023
Q3
$4.26M Sell
73,331
-15,411
-17% -$944K 0.61% 34
2023
Q2
$5.68M Buy
88,742
+4,728
+6% +$317K 0.74% 23
2023
Q1
$5.82M Sell
84,014
-10,392
-11% -$733K 0.8% 18
2022
Q4
$6.79M Sell
94,406
-2,730
-3% -$206K 0.88% 20
2022
Q3
$6.91M Sell
97,136
-1,231
-1% -$89.3K 0.93% 19
2022
Q2
$7.57M Sell
98,367
-1,322
-1% -$101K 0.97% 16
2022
Q1
$7.28M Buy
99,689
+260
+0.3% +$17.5K 0.78% 21
2021
Q4
$6.2M Sell
99,429
-2,530
-2% -$148K 0.62% 31
2021
Q3
$6.03M Sell
101,959
-7,160
-7% -$472K 0.62% 32
2021
Q2
$7.29M Buy
109,119
+2,120
+2% +$138K 0.67% 30
2021
Q1
$6.75M Sell
106,999
-2,180
-2% -$136K 0.67% 32
2020
Q4
$6.77M Sell
109,179
-4,672
-4% -$287K 0.62% 39
2020
Q3
$6.86M Sell
113,851
-2,581
-2% -$155K 0.62% 40
2020
Q2
$6.85M Sell
116,432
-50
-0% -$2.99K 0.66% 35
2020
Q1
$6.49M Sell
116,482
-710
-0.6% -$43.4K 0.7% 34
2019
Q4
$7.52M Sell
117,192
-28,680
-20% -$1.64M 0.64% 36
2019
Q3
$7.4M Sell
145,872
-2,520
-2% -$118K 0.54% 50
2019
Q2
$6.73M Sell
148,392
-58,058
-28% -$2.7M 0.47% 62
2019
Q1
$9.85M Buy
206,450
+5,090
+3% +$254K 0.49% 59
2018
Q4
$10.5M Sell
201,360
-2,260
-1% -$121K 0.59% 46
2018
Q3
$12.6M Buy
203,620
+6,540
+3% +$388K 0.58% 46
2018
Q2
$10.9M Buy
197,080
+7,560
+4% +$408K 0.55% 49
2018
Q1
$12M Sell
189,520
-7,960
-4% -$512K 0.62% 43
2017
Q4
$12.1M Sell
197,480
-10,867
-5% -$680K 0.59% 45
2017
Q3
$13.3M Buy
208,347
+18,976
+10% +$1.11M 0.7% 35
2017
Q2
$10.6M Buy
189,371
+26,821
+17% +$1.46M 0.62% 43
2017
Q1
$8.84M Sell
162,550
-14,550
-8% -$798K 0.55% 50
2016
Q4
$10.3M Sell
177,100
-150
-0.1% -$8.2K 0.67% 35
2016
Q3
$9.56M Buy
177,250
+38,610
+28% +$2.48M 0.64% 37
2016
Q2
$10.2M Sell
138,640
-6,710
-5% -$474K 0.77% 29
2016
Q1
$9.29M Buy
145,350
+28,640
+25% +$1.81M 0.72% 36
2015
Q4
$8.03M Buy
116,710
+9,260
+9% +$612K 0.66% 38
2015
Q3
$6.36M Sell
107,450
-10,670
-9% -$677K 0.6% 44
2015
Q2
$7.86M Sell
118,120
-2,260
-2% -$149K 0.7% 39
2015
Q1
$7.76M Buy
120,380
+7,270
+6% +$455K 0.68% 36
2014
Q4
$6.68M Buy
113,110
+7,020
+7% +$396K 0.64% 38
2014
Q3
$5.43M Buy
106,090
+7,470
+8% +$373K 0.55% 47
2014
Q2
$4.78M Buy
98,620
+2,910
+3% +$143K 0.48% 51
2014
Q1
$4.97M Buy
95,710
+81,240
+561% +$4.32M 0.52% 47
2013
Q4
$769K Sell
14,470
-2,070
-13% -$105K 0.08% 242
2013
Q3
$765K Sell
16,540
-1,000
-6% -$43.9K 0.08% 272
2013
Q2
$784K Buy
+17,540
New +$761K 0.08% 265

Other funds holding BMY

Twin Capital Management's BMY Position: Q1 2026 in Review

Twin Capital Management increased its Bristol-Myers Squibb (BMY) stake by 0.28% in Q1 2026, buying an estimated $12.7K and bringing the position to 78,220 shares worth $4.74M. The position accounts for 0.61% of the portfolio, ranked #30.

Twin Capital Management first reported a position in BMY in Q2 2013 and has held it in 52 quarters since. The position peaked at $13.3M in Q3 2017. 2,520 funds tracked by Wall St. Rank hold BMY as of Q1 2026.

  • Twin Capital Management held 78,220 shares of Bristol-Myers Squibb worth $4.74M as of Q1 2026.
  • Twin Capital Management bought 218 Bristol-Myers Squibb shares in Q1 2026, an estimated $12.7K.
  • Bristol-Myers Squibb made up 0.61% of Twin Capital Management's portfolio in Q1 2026, its #30 holding.
  • Twin Capital Management first reported a position in Bristol-Myers Squibb in Q2 2013 and has held it in 52 quarters since.
  • Twin Capital Management's Bristol-Myers Squibb position peaked at $13.3M in Q3 2017.
  • 2,520 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q1 2026.

Based on Twin Capital Management's 13F filing for Q1 2026, filed 5 May 2026.